Form 8-K/A - Current report: [Amend]
SEC Accession No. 0001213900-24-100994
Filing Date
2024-11-21
Accepted
2024-11-21 16:15:11
Documents
15
Period of Report
2023-12-11
Items
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 3 TO FORM 8-K ea0221908-8ka3_aditxt.htm   iXBRL 8-K/A 34615
2 UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS OF EVOFEM BIOSCIENCES, INC ea022190801ex99-1_aditxt.htm EX-99.1 569911
3 UNAUDITED PRO FORMA CONSOLIDATED FINANCIAL STATEMENTS AS OF AND FOR THE NINE MON ea022190801ex99-2_aditxt.htm EX-99.2 269010
  Complete submission text file 0001213900-24-100994.txt   1155535

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE adtx-20231211.xsd EX-101.SCH 3009
5 XBRL LABEL FILE adtx-20231211_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE adtx-20231211_pre.xml EX-101.PRE 22355
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0221908-8ka3_aditxt_htm.xml XML 4953
Mailing Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219
Business Address 737 N. FIFTH STREET, SUITE 200 RICHMOND VA 23219 909-488-0844
Aditxt, Inc. (Filer) CIK: 0001726711 (see all company filings)

EIN.: 823204328 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K/A | Act: 34 | File No.: 001-39336 | Film No.: 241484540
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)